Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 20/20 | 1.00 |
| ▸ | UGCG | Q16739 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18309554 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL29359568 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL12615333 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL19844439 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL12615329 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| SCHEMBL15579449 | 0.85 | NTMT1 (0.81) | NTMT1UGCG | |
| SCHEMBL19837241 | 0.84 | NTMT1 (0.80) | NTMT1UGCG | |
| Venglustat SCHEMBL31522597 | 0.84 | NTMT1 (0.83) | NTMT1UGCG | |
| Venglustat SCHEMBL29358474 | 0.84 | NTMT1 (0.83) | NTMT1UGCG | |
| SCHEMBL16006996 | 0.79 | NTMT1 (0.66) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION | 2023-11-23 | — | — | US | disclosed |
| WO-2022024062-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200124624-A1 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | GENZYME CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2018-02-08 | — | — | US | disclosed |
| WO-2017165766-A2 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | GENZYME CORPORATION (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200124624-A1 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | PSMG3, PMP22, PLP2 | NTMT1 2661/4885UGCG 101/4885 |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | NTMT1 1778/4885UGCG 2762/4885 |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GBA1, GBA2, GALC | NTMT1 684/4885UGCG 13/4885 |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, GALC | NTMT1 2471/4885UGCG 84/4885 |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | NTMT1 1778/4885UGCG 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.